| Name | BiVictriX Therapeutics |
|---|---|
| Epic | BVX |
| Isin | GB00BNXH3K91 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 10.00p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £8.25 | Debt ratio | n/a |
| Shares in issue | 82.53 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -73.2 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -3.78 | 52-week high / low | 7.50p / 14.00p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | BiVictriX Therapeutics |
|---|---|
| Address | Mereside, Alderley Park ,Alderley Edge, Macclesfield, United Kingdom, SK10 4TG |
| Telephone | |
| Website | http://www.bivictrix.com/ |
| Director | Position |
|---|---|
| Ms Tiffany Jane Thorn | CEO |
| Dr Michael Kauffman | Non-Executive Chairman |
| Mr William Drummond Paris | Senior Independent Non-Executive Director |
| Mr Susan Day Lowther | Independent Non-Executive Director |
| Prof Robert Edward Hawkins | Independent Non-Executive Director |
| Assets £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Reporting date | 31/12/22 | 31/12/21 | 31/12/20 |
| Intangible asssets and goodwill | n/a | n/a | n/a |
| Investments and other non-current assets | n/a | n/a | n/a |
| Total non-current assets | 0.57 | 0.34 | 0.06 |
| Inventory / work in progress | n/a | n/a | n/a |
| Trade and other receivables | 0.68 | 0.48 | 0.06 |
| Cash and equivalents | 3.29 | 6.06 | 0.86 |
| Other current assets and asset held for resale | n/a | n/a | 0.08 |
| Total of all assets | 4.54 | 6.88 | 1.07 |
| Liabilities £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Short term liabilities | 0.39 | 0.38 | 0.33 |
| Long term liabilities | 0.19 | 0.18 | 0.67 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 0.58 | 0.55 | 1 |
| Net assets £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Net assets | 3.96 | 6.33 | 0.07 |
| Equity £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Share capital | 0.66 | 0.66 | 0.66 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | -6.35 | -3.85 | -1.52 |
| Share premium account | 12.05 | 12.05 | 1.43 |
| Total equity | 3.96 | 6.33 | 0.07 |
| Income £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -2.98 | -1.89 | -0.49 |
| Pre-tax profit | -2.97 | -2.53 | -0.51 |